## UNH: UnitedHealth Group Incorporated - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.26 indicates fundamental undervaluation. Quality metrics strong (ROE 18%).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($316.09)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. UnitedHealth Group Stock (UNH) Today: Price, Breaking News, Analyst Forecasts, and What Investors Should Watch Into the Close**
- Source: ts2.tech | 20251226T194731 | Neutral | Relevance: 100%
- UnitedHealth Group (UNH) shares are modestly up in a thinly traded post-Christmas session, influenced by a "holiday hangover" despite broader market seasonal tailwinds. Key drivers for investor sentiment include operational changes following external audits, ongoing DOJ scrutiny regarding Medicare Advantage billing, required divestitures from the Amedisys acquisition, and renewed political pressure on health insurance premiums. Investors are keenly awaiting the Q4 2025 earnings and 2026 guidance call on January 27, 2026, which is expected to be a significant catalyst given the current volatility and wide divergences in analyst forecasts.

**2. UnitedHealth Group (UNH) Stock Today: Weekend Market Close, Fresh Headlines, Analyst Targets, and What to Watch Before Mondayâ€™s Open**
- Source: ts2.tech | 20251228T154258 | Neutral | Relevance: 100%
- UnitedHealth Group (UNH) ended the weekend near $332, with investors balancing recovery potential against execution and regulatory risks. Key headlines include Barron's highlighting the need to rebuild confidence after Medicare Advantage disruption and a Wall Street Journal investigation into insurer-owned pharmacy practices. Investors are keenly watching for the Jan. 27, 2026, earnings release and 2026 guidance, which is expected to be a major catalyst for the stock.

**3. PineStone Asset Management Inc. Decreases Stake in UnitedHealth Group Incorporated $UNH**
- Source: MarketBeat | 20251228T130911 | Neutral | Relevance: 100%
- PineStone Asset Management Inc. has reduced its Q3 stake in UnitedHealth Group by 6.6%, selling 54,732 shares, but UNH remains its 21st-largest holding valued at $267.5 million. UnitedHealth reported strong Q3 earnings, beating EPS estimates, with revenue up 12.2% year-over-year, and pays an annualized dividend of $8.84. While institutional ownership is high and includes a significant stake by Berkshire Hathaway, analyst consensus for UNH is currently a "Hold" with an average price target of $385.54.

**4. Valley National Advisers Inc. Purchases 6,375 Shares of UnitedHealth Group Incorporated $UNH**
- Source: MarketBeat | 20251228T125544 | Somewhat-Bullish | Relevance: 100%
- Valley National Advisers Inc. significantly increased its stake in UnitedHealth Group (UNH) by 592.5%, purchasing 6,375 shares to hold a total of 7,451 shares valued at approximately $2.57 million. Several other major institutional investors, including Norges Bank and Berkshire Hathaway, also hold substantial positions in UNH, bringing total institutional ownership to 87.86%. Analysts generally rate UNH as "Hold" with an average price target of $385.54, and the company recently beat EPS expectations and announced a quarterly dividend of $2.21 per share.

**5. Greenwood Capital Associates LLC Has $5.20 Million Stock Position in UnitedHealth Group Incorporated $UNH**
- Source: MarketBeat | 20251228T113700 | Bullish | Relevance: 100%
- Greenwood Capital Associates LLC significantly increased its stake in UnitedHealth Group (UNH) by 85.5% in Q3, now owning shares valued at about $5.20 million. While several analysts have issued positive ratings and increased price targets, the overall consensus for UNH remains a "Hold" with an average price target of $385.54. UnitedHealth Group reported strong quarterly earnings, beating expectations with EPS of $2.92, and displayed robust revenue growth and a market capitalization of nearly $300.5 billion.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 23 ($0.00M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 39.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (-0.3%)
- Blackrock Inc.: 8.2% (-1.4%)
- State Street Corpora: 4.9% (-1.8%)
- JPMORGAN CHASE & CO: 4.1% (+85.6%)
- Geode Capital Manage: 2.4% (+2.2%)

### Key Risks

1. Long-term trend broken: trading 5.7% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.26 suggests fair value with growth premium. Forward P/E 18.7x stretched relative to 9% growth. Balance sheet: $5.1B free cash flow. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $300.6B |
| Beta | 0.43 |
| 52W Range | $234.60 - $606.36 |
| Short Interest | 1.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.26 |
| Forward P/E | 18.7 |
| Current P/E | 20.3 |
| YoY Growth | 8.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at -0.3% (minimal 5-day change). Below STRENGTH zone by 4.3pp (needs >4.0% for momentum thesis). MRS_5 turning positive (1.0%) - potential reversal signal. Below SMA200 (0.94x), long-term trend not supportive. RSI neutral at 52. OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.29% (CS: 49) | Neutral |
| RSI_14 | 51.5 | Neutral |
| MACD Histogram | -0.01 | Bearish |
| vs SMA20 | 1.004x | Above |
| vs SMA50 | 0.991x | Below |
| vs SMA200 | 0.943x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $331.85
- **Stop Loss:** $316.09 (4.7% risk)
- **Target:** $363.37 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 83
- **Position Value:** $27,543.55
- **Portfolio %:** 27.54%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-01-15 (Est: $2.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.81 | $2.92 | +4.0% |
| 2025Q2 | $4.45 | $4.08 | -8.2% |
| 2025Q1 | $7.29 | $7.20 | -1.3% |
| 2024Q4 | $6.74 | $6.81 | +1.1% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*